Harms of Synthetic Cannabinoid Receptor Agonists (SCRAs) and Their Management

Dr Dima Abdulrahim and Dr Owen Bowden-Jones on behalf of the NEPTUNE group

This publication of the Novel Psychoactive Treatment UK Network (NEPTUNE) is protected by copyright. The reproduction of NEPTUNE guidance is authorised, provided the source is acknowledged.

© 2016 NEPTUNE (Novel Psychoactive Treatment UK Network)

NEPTUNE (Novel Psychoactive Treatment UK Network)
Club Drug Clinic
Central and North West London NHS Foundation Trust (CNWL)
69 Warwick Road
Earls Court
SW5 9HB
www.neptune-clinical-guidance.co.uk

The guidance is based on a combination of literature review and expert clinical consensus. We accept no responsibility or liability for any consequences arising from the use of the information contained in this document.

The recommended citation of this document is:
Abdulrahim D, Bowden-Jones O, on behalf of NEPTUNE group. Harms of Synthetic Cannabinoid Receptor Agonists (SCRAs) and Their Management. London: Novel Psychoactive Treatment UK Network (NEPTUNE), 2016.

NEPTUNE is funded by the Health Foundation, an independent charity working to improve the quality of health care in the UK.
www.health.org.uk

This document has been written as part of the wider suite of clinical guidance and tools that aim to provide evidence-based knowledge to inform the management in clinical practice of harms related to the use of ‘club drugs’. It is a supplement to, and should be read in conjunction with, Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances (www.neptune-clinical-guidance.co.uk).

Quality of the research evidence
The international evidence on the management of the acute and chronic harms related to the use of SCRAs is limited and still emerging; randomised control trials in particular are not available. Evidence mainly consists of case reports and series and a small number of prospective observational studies, retrospective cohort studies and analysis of patient records. Despite these limitations, data/evidence from these sources is relatively consistent.

Editorial production and page design by Ralph Footring Ltd, www.footring.co.uk
# Contents

1. Introduction 1

2. Pharmacology and effects of SCRAs 3
   Onset and duration of action 4
   Potency 4
   Effects 4

3. Harms of acute toxicity 5
   Acute toxicity 5
   SCRA-induced psychosis 6

4. Management of acute harms 7
   SCRA intoxication 7
   When to call an ambulance 8
   Identification and assessment of acute harms in acute care settings 8
   Managing acute intoxication and toxicity 8
   Care bundle 9
   Discharging patients: brief advice and information 10

5. Harms associated with frequent and long-term (chronic) use 11
   Harmful and dependent use 11
   Physiological, psychological and psychiatric long-term effects 11

6. Management of the harms associated with long-term and frequent use 13

7. Drug interactions 14

References 15
1. Introduction

Synthetic cannabinoid receptor agonists (SCRAs) are a large group of drugs, which have a strong effect on the endocannabinoid system. Approximately 200 different SCRA compounds are now available. In 2015, they represented the largest group of novel psychoactive substances (NPS) reported globally and in Europe.

Products used for recreational purposes are typically an inert herbal product that has been sprayed with one or more SCRAAs (Figure 1) and that is smoked. Oral, powder and injectable SCRA preparations have also been reported to be available; in addition they are sold as an e-liquid (the liquid used in electronic cigarettes).

There are a large number of brands sold on the UK market (Figure 2), containing different SCRAAs, with different levels of potency. Herbal products are marked ‘not for human consumption’ but are presented in attractive and colourful packaging.

Figure 1. SCRA products such as Spice are typically sold as an inert herbal product that has been sprayed.

Figure 2. The packaging of a selection of products and brands.
What particular brands contain is likely to vary, and certainly brand names are not reliable indicators of what is consumed. Analytical tests have shown that the cannabinoid constituents and dosage can vary greatly both between products and between batches of the same brand. There may even be differences within the same package, if for example the SCRA has been sprayed unevenly on the herbal product. There is also evidence that some products contain a combination of different SCRA compounds.

SCRA products in the UK are sometimes known generically as ‘Spice’, the name of a popular brand. However, not all products labelled ‘Spice’ are SCRAs. Stimulant drugs also branded ‘Spice’ have been sold (Figure 3), suggesting once again the hazards associated with relying on brand names.

At the time of writing of the report, the Psychoactive Substance Act 2016 had just come into force. The trade in ‘legal highs’ became illegal and the police were given the power to shut down ‘headshops’ and UK-based on-line sellers. It is too early to identify its impact on patterns of substance use, including ‘distribution’ and the packaging of what were previously ‘legal highs’, although there is some anecdotal evidence that SCRAs are increasingly being sold in plain plastic packets by street dealers. It is not yet clear whether this represents a more lasting trend and whether SCRAs will be sold on the illicit market (and if so how). More research is needed.

In the UK, information on the prevalence of use of SCRAs remains limited. The use of SCRAs appears to be more prevalent among prisoners and homeless populations, and concerns have been voiced about its impact on these groups.

![Figure 3. Stimulant drug (left) branded as ‘Spice’ (front and back of package shown right)
2. Pharmacology and effects of SCRAs

SCRAs are a large and chemically diverse group of molecules with some functional similarity to natural cannabis, the chief psychoactive constituent of which is delta-9-tetrahydrocannabinol (THC), as well as to other phytocannabinoids. However, many of the SCRAs are not structurally related to natural cannabinoids or THC. Table 1 compares SCRAs with natural cannabis.

Table 1. Comparison of SCRAs and natural cannabis

<table>
<thead>
<tr>
<th></th>
<th>Natural cannabis</th>
<th>SCRAs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary psychoactive</td>
<td>THC (delta-9-tetrahydrocannabinol)</td>
<td>One or more of a wide array of molecules that stimulate the brain’s cannabinoid receptors</td>
</tr>
<tr>
<td>substance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presence of cannabidiol (CBD)</td>
<td>Contains CBD</td>
<td>Do not contain CBD</td>
</tr>
</tbody>
</table>

Over 200 SCRAs have been detected on the global drug market, with an estimated 150–160 available to UK consumers. There are wide differences between the various SCRAs, including in metabolism, potency, toxicity and duration of effects.

- Both SCRAs and natural cannabis (THC) bind to the CB1 and CB2 receptors. Generally speaking, the greater the affinity to the CB1 receptor, the higher is the psycho-pharmacological activity of the agonist compound.

- SCRAs usually have a much higher affinity for those receptors than natural cannabis. As a result, SCRAs can produce stronger effects, especially those that act as full agonists on the CB1 receptor.

- Although SCRAs produce effects that have similarities to those produced by THC, they are not the same. SCRAs may have other biological actions, which may explain some of the differences in severity and features of toxicity between SCRAs and natural cannabis.

- Some SCRA compounds incorporate indole-derived moieties, which are structurally similar to serotonin and may be associated with particularly high levels of activation of serotonin receptors.

- It has been suggested that at high doses some SCRA compounds may also possess monoamine oxidase and 5-HT reuptake inhibitory properties, which may increase the risk of serotonin syndrome. (For more information on the serotonin syndrome see NEPTUNE, Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances, p. 147.)
• In contrast to natural cannabis, SCRAs do not contain cannabidiol (CBD), a chemical which moderates the effects of THC and may possess anxiolytic, antipsychotic and anti-craving properties.

• It has been reported that, in comparison with natural cannabis, SCRAs are characterised by quicker onset of effects, significantly shorter duration of action, worse hangover effects and more intense visual hallucinations, paranoid feelings and behavioural disturbances.

Onset and duration of action
The onset of the action of SCRAs is usually within minutes of smoking, but longer following oral consumption. The length of the effect of SCRAs varies. Although there are no controlled studies in humans, there are reports that the duration of action of SCRAs can range from 1–2 hours for some compounds to up to 6–8 hours for others.

Potency
Most SCRAs are more potent than natural cannabis, and some have long half-lives. There are differences between the various SCRAs, with some having significantly greater potency than others. Products containing SCRAs can range from those with potency similar to natural cannabis to those that are up to 100–800 times more potent than natural cannabis typically is.

Effects
The desired effects of SCRAs include relaxation, altered consciousness, disinhibition and euphoria, and a state of ‘being energised’. Reports describe sedative-like effects, and hallucinogenic effects have also been reported. People who use SCRAs have indicated that they can produce unique subjective effects, discernible from the effects of natural cannabis, and there are suggestions that when products are smoked people are able to differentiate between the effects of natural cannabis and those of SCRAs.
3. Harms of acute toxicity

Acute toxicity

The evidence base on the harms associated with the use of SCRAs and their management is still emerging and remains limited. Little is known about the metabolism and toxicology of SCRAs in humans. It cannot be assumed that the risks associated with their use will be comparable with those of cannabis and there are concerns that they may have a greater potential to cause harm. SCRA products can also have unpredictable effects. There is emerging evidence that the risks of requiring emergency medical treatment as consequence of using SCRAs are much greater than for natural cannabis. There is also evidence that some more recent formulations may be more potent than earlier ones and be associated with greater harms.

Box 1. Symptoms of acute toxicity

The literature on the adverse effects of SCRAs remains limited, but the following adverse effects linked to the use of the drugs have been reported.

**Neurological, cognitive and psychiatric effects**
- Anxiety, irritability and psychosis-like effects
- Inappropriate or uncontrolled laughter, anger, sadness, flat affect, depression and suicidal thoughts, excitability, agitation, combativeness, aggressiveness, thought disorganisation, panic attacks, paranoid thinking, delusions and auditory and visual hallucinations, changes in perception, acute psychosis
- Reduced levels of consciousness; coma
- Numbness, tingling, light-headedness, dizziness, pallor, tinnitus, diaphoresis, tremor, somnolence, syncope, unresponsiveness, nystagmus and convulsions
- Short-term memory and cognitive deficits, confusion, sedation and somnolence, thought blocking, nonsensical speech, amnesia, increased focus on internal unrest

**Cardiovascular effects**
- Tachycardia, hypertension, hypotension, hypokalaemia, chest pain and palpitations, myocardial ischaemia, myocardial infarction, ischaemic strokes
- Neuromuscular and musculoskeletal effects
- Hypertonia, myoclonus, myalgia, rhabdomyolysis

**Renal effects**
- Acute kidney injury

**Other effects**
- Hyperglycaemia, hypoglycaemia, acidosis, respiratory acidosis, cold extremities, dry mouth, dyspnoea, mydriasis, vomiting, loss of sight and speech

**Serotonin syndrome**
In addition, SCRAs have been linked to the serotonin syndrome. For more information on serotonin syndrome see NEPTUNE, *Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances*, p. 147.
The symptoms of acute toxicity are listed in Box 1. Acute SCRA toxicity appears to have a similar clinical presentation to the toxicity of natural cannabis and THC, although differences have been reported, with convulsions and hypokalaemia particularly noted. At least some SCRAs have led to severe and even life-threatening intoxication when taken in sufficiently large doses, particularly in the case of compounds that act as a full agonist at the CB1 receptor.

Individual susceptibility to SCRA-related harm remains unclear. The harmful effects of SCRA may be greater in SCRA users who are drug naïve or those with only limited previous exposure to cannabis.

Reported harms associated with SCRAs include a range of psychiatric problems, the most prominent of which are anxiety (which can be severe), irritability, agitation and psychosis-like effects. Other adverse effects include negative mood changes, hallucinosis and ‘hangover’ effects.

Common physical effects of SCRAs include tachycardia and nausea. SCRAs are also reported to be cardiotoxic. Widely reported sympathomimetic effects include seizures, hypertension, diaphoresis, hyperthermia, agitation and aggression. SCRAs have also been associated with hypotension and linked to severe kidney injury and rhabdomyolysis (muscle damage).

There has been particular concern over a number of SCRAs, including MDMB-CHMICA, which have been associated with severe adverse effects across Europe.

**SCRA-induced psychosis**

Psychotic symptoms appear to occur relatively frequently following SCRA consumption. More research is needed, but this may be linked to the high potency of the drugs and the fact that, unlike natural cannabis, SCRAs do not contain cannabidiol (CBD), a chemical which appears to possess antipsychotic properties.

It has been suggested that SCRA users are more likely than people who use natural cannabis to experience hallucinations and delusions.

In comparison with psychotic episodes associated with the use of natural cannabis, psychotic episodes associated with SCRAs occur more frequently, are more severe and are linked to greater agitation.

- There are reports of SCRA-associated acute transient psychosis, as well as reports that some individuals may experience psychosis that persists for weeks after the acute intoxication, or even longer.

- Psychosis has been reported in otherwise healthy people; however, there is particular concern about the risk of SCRAs precipitating psychosis in vulnerable individuals, including those with a current or previous history of psychosis.
4. Management of acute harms

SCRA intoxication

The ingestion of SCRA will not necessarily have adverse effects that require an intervention.

- Adults who have used SCRAs and who do not present with symptoms of acute intoxication are unlikely to require any monitoring, investigation or treatment.
- Even when the person presents with symptoms of SCRA intoxication, these will usually be self-limiting and resolve spontaneously.

Some people will, however, suffer SCRA-related adverse effects and these could be severe. Acute SCRA intoxication has been characterised as generally short-lived, with reported symptoms including elevated heart rate and blood pressure, visual and/or auditory hallucinations, mydriasis, agitation, anxiety, hyperglycaemia, dyspnoea, tachypnoea, nausea and vomiting.

---

Box 2. Guidance on when to call the emergency services for unwell recreational drug users

Call 999 or 112 if any one of the following is present:

- **Unconsciousness** – if the patient does not respond to vocal commands, requires painful stimulus (e.g. pressure across the fingernails) to respond, or does not respond at all
- **Significant agitation** (e.g. pacing around the room) or aggression, not settling within 15 minutes
- **Seizures** (e.g. a convulsion similar to an epileptic fit)
- **Breathing difficulties**, such as fast breathing rate, not settling within 5 minutes
- **Heart rate** over 140 beats per minute, not settling within 5 minutes
- **Temperature** over 38.5°C, not settling after about 5 minutes of rest or, if no thermometer is available, if very flushed and feels very hot
- **Blood pressure**: Systolic (‘upper pressure’) over 180 mmHg, or diastolic (‘lower pressure’) over 110 mmHg on two repeated measurements
- **If there are any other concerns** (e.g. severe headache, chest pain)

If in doubt call 999 or 112

When to call an ambulance

As part of its aims to improve the recognition and assessment of acute drug toxicity by training staff working in recreational settings, the Euro-Den project has developed guidance on when to call the emergency services (by telephoning 112 or 999 in the UK) for unwell recreational drug users. See Box 2 for information on when to call emergency services.

Identification and assessment of acute harms in acute care settings

SCRAs cannot be detected by the screening tests for THC, the active ingredient in natural cannabis. Clinicians working in emergency care should be vigilant for SCRA-induced toxicity despite negative drug-screening results. Laboratory techniques have been developed to detect some SCRA, but these are currently not widely available and do not detect all SCRA; the regular appearance of new compounds is challenging because of the lack of reference samples in laboratories to identify them. In addition, more than one SCRA can be found within the same mixture or product.

The identification of acute SCRA toxicity is also complicated by the unpredictable effects of the drug and the lack of a clear toxidrome to distinguish SCRA from other recreational substances. There are no pathognomonic features of SCRA toxicity.

SCRA intoxication should be included in the differential diagnosis of adolescents or young adults presenting with an acute and otherwise unexplained alteration of mental state associated with autonomic disturbances. The use of SCRA should also be considered in atypical presentations, such as acute unexplained kidney injury or myocardial infarction in an otherwise healthy young person.

Managing acute intoxication and toxicity

For up-to-date information on the management of the harms of SCRA consult TOXBASE® (www.toxbase.org). Non-UK readers should consult their local or national guidelines.

The management of SCRA toxicity is symptomatic and supportive, as no antidotes exist.

- Hydration and monitoring may be enough for patients with mild to moderate intoxication.
- Supportive treatment is dependent on a patient’s specific presentation (e.g. agitation, delirium, hypertension, convulsions).

In a minority of cases, SCRA consumption can be associated with severe cardiovascular, cerebrovascular, neurological, psychiatric and renal effects. Interventions will focus on the prevention of rhabdomyolysis and the monitoring of cardiac or cerebral ischaemia.
There is some evidence that benzodiazepines are of benefit to patients with symptoms of anxiety, panic and agitation. The use of intravenous benzodiazepines has been reported for the management of seizures and in some cases of SCRA-related psychosis.

There are a small number of reports describing antipsychotic medication being indicated for some patients, especially those who present with agitation or aggression, when the patient has a history of psychotic disorders, and when the psychotic symptoms do not remit with supportive care. There are also a small number of reports that describe antidepressants being administered in cases where there is concurrent depression.

Drug interactions are discussed in section 7 of this document.

**Care bundle**

A number of steps must be carried out to support the effective management of the adverse effects of SCRAs at the time of presentation to hospital and beyond. This can be enhanced through, for example, a care bundle, which is a quality improvement tool that supports reliable and effective care (see www.ihi.org/Topics/Bundles). It provides a small, straightforward set of evidence-based practices that, when performed collectively and reliably, improve outcomes. Compliance with components of the care

---

**Box 3. A care bundle for people experiencing acute harm from SCRA use: assessment and management**

*Tick when action completed*

- **Base your diagnosis of acute SCRA intoxication on clinical assessment and recognition of symptoms of toxicity. Do not depend on urinalysis. SCRAs cannot be detected by screening tests for THC. Many new SCRA compounds will not appear in existing tests for SCRAs. Also, brand names can be misleading. Do not depend on the name to determine the type of compound, its potency, duration of action or specific harms.**

- **Consider the use of more than one substance, including alcohol (polydrug use).**

- **Determine ingestion mode of SCRA.** SCRAs are typically smoked. The onset of effects is much longer in cases of oral ingestion of SCRAs.

- **Provide supportive and symptomatic care.** Refer to TOXBASE® for up-to-date information on the management of acute SCRA harms (www.toxbase.org).

- **Complete the Illicit Drug Reactions Reporting and Intelligence System (IDRRIS) form of Public Health England (PHE) and the Medicines and Healthcare Products Regulatory Agency (MHRA) (to be launched in autumn 2016).**

*At discharge*

- **Brief advice and information on behaviour change and harm reduction. Where harmful or dependent use has been identified, signpost or refer to specialist drug treatment and recovery services.**

- **Give patient information and harm-reduction leaflet (see Box 4).**
bundle can easily be recorded by a ‘Yes’ or ‘No’ (or tick or cross). Care bundles do not replace clinical judgement, nor diminish responsibilities of clinicians. A care bundle for the management of acute SCRA intoxication is outlined in Box 3.

**Discharging patients: brief advice and information**

Most patients will benefit from information, brief advice and signposting. This may take no longer than a few minutes, and could form part of a wider conversation about a health problem. The aim is to address SCRA-related harms and their reduction. The focus should also be on making changes to substance use in order to improve both health and social outcomes (for more information see www.neptune-clinical-guidance.co.uk).

Patients may also benefit from printed information on the reduction of SCRA-related harms which they can take with them. An example of what to include in a patient information sheet is given in Box 4.

A number of organisations also offer harm-reduction advice to people who use drugs, such as Crew (www.crew2000.org.uk) and Frank (www.talktofrank.com).

**Box 4. Harm reduction advice for SCRA users**

- There is no safe way to use synthetic cannabinoid receptor agonists (e.g. ‘Spice’).
- SCRAs are not the same thing as natural cannabis.
- SCRAs appear to be stronger than natural cannabis and more unpredictable.
- SCRAs usually vary from batch to batch, so different packets can produce different effects, even if the packaging looks the same.
- Different SCRA compounds have different strengths and potency, with some significantly stronger than others.
- If you are going to use an SCRA, start with small doses. Consider a quantity no larger than a match head.
- Wait before the effects have gone before smoking some more.
- Synthetic cannabinoids should not be taken on their own, but always with a ‘mixer’ (e.g. tobacco or dried herbs).
- SCRAs should not be used together with natural cannabis.
- You should avoid smoking synthetic cannabinoid products through pipes or ‘bongs’, as it can increase the risk of an overdose or bad reaction.
- Regular use of SCRAs can lead to dependence (addiction) and withdrawal.
- SCRAs can cause severe harms. If you experience a sustained period of fast heart rate or chest pains, call an ambulance.
- SCRAs can increase anxiety or paranoia. Only use them in an environment where you feel safe and with people you trust. If you suffer from anxiety or mental health problems, avoid using them.
- Avoid mixing SCRAs with other drugs, medicines and alcohol.
- Do not drive or operate machinery under the influence of SCRAs.
5. Harms associated with frequent and long-term (chronic) use

Harmful and dependent use

The evidence remains limited, but research has shown that SCRAs have a potential for misuse and dependence.

- There is increasing evidence that the chronic use of SCRAs may be associated with tolerance. Tolerance may develop more quickly for SCRAs than for natural cannabis.
- There are some reports of withdrawal symptoms following prolonged and frequent use (see Box 5).

<table>
<thead>
<tr>
<th>Box 5. Reported features of SCRA withdrawal</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Headaches</td>
</tr>
<tr>
<td>• Anxiety</td>
</tr>
<tr>
<td>• Coughing</td>
</tr>
<tr>
<td>• Insomnia/sleep disturbance</td>
</tr>
<tr>
<td>• Impatience, difficulty concentrating</td>
</tr>
<tr>
<td>• Anger/irritability</td>
</tr>
<tr>
<td>• Restlessness</td>
</tr>
<tr>
<td>• Nausea</td>
</tr>
<tr>
<td>• Depression</td>
</tr>
<tr>
<td>• Craving</td>
</tr>
<tr>
<td>• Diaphoresis</td>
</tr>
<tr>
<td>• Tremor</td>
</tr>
<tr>
<td>• Hypertension</td>
</tr>
<tr>
<td>• Tachycardia</td>
</tr>
</tbody>
</table>

Physiological, psychological and psychiatric long-term effects

We know little about the long-term effects and harms of SCRA use.

- Although no experimental data are available, because SCRAs are lipophilic compounds, it would be expected that they would have a high volume of distribution. It is therefore likely that chronic use will lead to accumulation of SCRAs and their metabolites in fat-containing compartments in the body. The clinical implications of this are as yet unclear.
- Psychosis has been reported among people who use SCRAs frequently (see section 3, p. 6, for more information on SCRA-induced psychosis). Some studies suggest that new-onset psychosis may be precipitated by repeated use or even single use of SCRAs.
- Cognitive impairment has been described with chronic daily use.
• There is speculation that some SCRAs, particularly the aminoalkylindoles, may have carcinogenic potential.

• There are reports that SCRAs can cause cannabinoid hyperemesis syndrome (persistent vomiting).

• SCRAs would be expected to be associated with lung disease, as they are mainly smoked. There is no evidence to draw upon as yet.

• Catatonic states induced by chronic persistent high-dose SCRA use have been reported.
6. Management of the harms associated with long-term and frequent use

Very little evidence is available on the management of the harmful or dependent use of SCRAs; it is suggested that clinicians adopt the evidence-based approaches used for other drugs – particularly natural cannabis.

There is no evidence to suggest that a particular approach is linked to successful outcomes for SCRA users.

Suggested psychological and social interventions include motivational approaches, relapse prevention and reintegration with non-using social networks.

No specific medications are indicated for SCRA harmful use or dependence and no substitute prescribing is currently available.

Symptomatic management of withdrawal symptoms may be indicated in some cases.

Whatever approaches are used, interventions should also address issues specific to SCRAs and to particular populations who appear to be using them. Underlying drivers of use can include misuse of other substances, mental health and physical health comorbidity, issues associated with homelessness and deprivation, and involvement in the criminal justice system and incarceration.

There is no risk-free way to use SCRAs, so it is important that people who continue using them have information to help them reduce adverse effects and harms.
7. Drug interactions

Information on the interactions of SCRAs with other drugs, including prescribed medication, is currently very limited. No guidance is available and decisions on prescribing medication should be made on a case-by-case basis.

Some of the interactions of SCRAs with other drugs may be similar to those of natural cannabis. It is possible that sedative medication may have stronger sedative effects when used with SCRAs. SCRAs may also increase the adverse effects of drugs with a similar side-effect profile.

Some SCRA compounds may be associated with activation of serotonin receptors. This implies that serotonergic therapeutic agents should be prescribed with care to minimise the risk of serotonin syndrome or poisoning (including SSRIs, MAOIs, St John’s wort etc.).

Drug interactions concerning (natural) cannabis may be applicable to SCRAs. Case reports suggest that the concurrent use of cannabis with tricyclic antidepressants (TCAs) or anticholinergic drugs can produce significant tachycardia, resulting from the beta-adrenergic effects of cannabis added to the anticholinergic effect of tricyclic antidepressants. It has been suggested that clinicians monitor the heart rate of patients receiving treatment with anticholinergic medication and who use cannabis.

As with patients who use natural cannabis, patients receiving treatment with protease inhibitors who also use SCRAs should receive regular monitoring of viral indicators to confirm the effectiveness of the antiviral treatment.
References

The full chapter on synthetic cannabinoid receptor agonists (SCRAs) published in Guidance on the Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances drew on the following references:


Dean A. Illicit drugs and drug interactions Illicit drugs and drug interactions. Australian Pharmacist. 2006;25(9).


"Synthetic Cannabinoid Receptor Agonists"


Synthetic Cannabinoid Receptor Agonists


